Targeted alpha therapy with 212Pb-NNV003 for the treatment of CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)

Conclusion: The study indicates that tumor targeting is independent of antibody dose up to a 100 μg/mouse (SA of 0.1 µCi/µg). 212Pb-NNV003 is a safe and effective method for the treatment of CD37 positive CLL and NHL in preclinical models, and future clinical testing is warranted.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Saidi, A., Maaland, A., Torgue, J., Heyerdahl, H., Dahle, J. Tags: Oncology, Basic and Translational (Basic Science) III Source Type: research